infusion; response; GvHD Leukemia relapse remains a limitation to the success of bone marrow transplantation (BMT). It occurs in about 20% of patients transplanted in first complete remission of acute leukemia and in first chronic phase of chronic myeloid leukemia (CML), but increases for patients transplanted with advanced disease. [1] [2] [3] Significant protection is conferred by donor T cells and the so-called graftversus-leukemia effect (GvL). 4 The latter hypothesis is supported by at least four orders of clinical observations: the impact on relapse of T-cell depletion (TCD), 5 the effect of high-dose cyclosporin (CyA) in the first 10 days post transplant, 6 the impact of graft-versus-host disease (GvHD) in its acute and chronic form 7 and the antileukemic effect of donor lymphocyte infusions (DLI), mainly in patients with CML. 8 It should be noted that these represent immune interventions at different time points after transplant. It is interesting that patients with acute lymphoblastic leukemia (ALL) are protected from relapse by acute and/or chronic GvHD, 7 but do not respond to DLI in most instances. 9 Indeed results of DLI in ALL patients have been so disappointing that some investigators believe GvL is less effective in ALL as compared to CML. [9] [10] [11] [12] The immune effect may however depend on the number of clonogenic leukemic cells, and the latter may vary at different time points after transplant, and in different diseases. In CML, post-transplant relapse may be sustained literally by 5 Ph positive stem cells, 13 thus explaining the high response rate in this disease.
Complications of DLI include pancytopenia and GvHD, leading to significant morbidity and mortality in a significant number of patients. [9] [10] [11] 14, 15 GvHD is dependent on the dose of T cells infused 16 and is seen mainly in programs using bulk-dose regimens (BDR) as compared to escalating-dose regimens (EDR). 17 Pancytopenia has also been reported, especially when donor-derived normal progenitors are insufficient to restore hematopoiesis. 18 Factors predictive of response have been reported to be a diagnosis of CML, the occurrence of GvHD post-DLI, [9] [10] [11] and time interval between BMT and DLI. 19 Despite the widespread use of DLI many unanswered questions remain, such as optimal timing, schedule of administration and factors predictive of response and GvHD. We report 593 DLI administered to 100 patients from June 1990 to December 2000, and factors predicting acute GvHD and response.
Material and methods

Patients
All patients were transplanted in our unit between 1984 and 1999. Bone marrow donors were HLA identical siblings (n ¼ 87), mismatched related donors (n ¼ 7) or matched unrelated donors (MUD) (n ¼ 6). Median age at DLI was 43 years (range 14-60). Patients were classified into two categories based on diagnosis: CML (n ¼ 51) and other malignant diseases (n ¼ 49). The latter comprised acute mycloid leukemia (AML) (n ¼ 19), ALL (n ¼ 10), lymphoproliferative disorders (LPD) (n ¼ 10, of which four were myeloma, four non-Hodgkin's lymphoma, two chronic lymphocytic leukemia), myelodysplasia (MDS) (n ¼ 7), idiopathic myelofibrosis (IM) (n ¼ 2), and essential thrombocythemia (ET) (n ¼ 1). BMT characteristics are outlined in Table 1 .
Relapse
The median interval between BMT and relapse was day +222 from BMT (range 30-3477). Type of relapse was subdivided into five groups: (1) molecular relapse (n ¼ 6: 3 CML+3 ALL), cytogenetic relapse (n ¼ 20: 18 CML+2 MDS), CML chronic phase or non-CML in complete hematologic remission after chemotherapy (n ¼ 24: 16 CML+8 AML), CML in accelerated/blastic phase (n ¼ 14) and resistant disease not responding to chemotherapy (n ¼ 36).
Donor lymphocyte infusions (DLI)
Lymphocytes were harvested from the original donors of the first transplant in all cases by leukapheresis. The 
Results
Response to DLI and type of relapse
The response to DLI was highest in patients with molecular relapse: 100%; followed by patients with cytogenetic relapse (16/18 CML, 2/2 MDS): 90%; chronic phase CML (12/16) or leukemia in complete remission (6/8 pts): 75%; CML in accelerate/blastic phase: 35.7% and, finally, resistant disease (leukemia not responding to chemotherapy): 0%. The actuarial probability of a complete response according to type of relapse was 100%, 100%, 86%, 38%, and 0%, respectively for the five groups ( Figure 1 ). Of interest are three ALL patients treated for molecular relapse, who entered a complete molecular remission following DLI. In univariate analysis, factors predicting response were type of relapse at DLI (Po0.0001), interval BMT-relapse longer than 222 days (P ¼ 0.002), pancytopenia post-DLI (P ¼ 0.004), a diagnosis of CML (P ¼ 0.004), T-cell depletion at BMT (P ¼ 0.03), early disease at BMT (P ¼ 0.03), and the occurrence of GvHD II-IV post-DLI (P ¼ 0.01) ( Table 2 ). In multivariate analysis significant predictors of response were type of relapse (Po0.0001), GvHD post-DLI (P ¼ 0.005) pancytopenia post-DLI (P ¼ 0.008) and a diagnosis of CML (P ¼ 0.04) ( Table 4) . There was no correlation between response and total number of CD3+cells infused (P ¼ 0.8), number of CD3+cells infused per time unit (number of CD3/time in days) (P ¼ 0.7) or duration of DLI treatment (P ¼ 0.3).
There was also no impact of concomitant treatment on response.
Relapse following DLI-induced response
A total of 46 patients were in remission after DLI: seven patients or 15% (three CML, three AML, one ALL) relapsed at a median interval of 240 days (120-730). The actuarial probability of remaining in complete remission at 5 years for all 46 patients is 85%.
Graft-versus-host disease (GvHD)
Acute GvHD (grades II-IV) occurred in 21 patients (21%): the proportion was 29% vs 12% for CML vs non-CML patients (P ¼ 0.03). Six patients developed acute GvHD grades III-IV. Chronic GvHD was seen in 6/51 CML patients compared to 0/49 non-CML patients (P ¼ 0.01).
In univariate analysis, factors predicting GvHD were: pancytopenia post-DLI (P ¼ 0.0009), T-cell depletion at the first transplant (P ¼ 0.01), number of DLI (o4) (P ¼ 0.01), a diagnosis of CML (P ¼ 0.03) ( Table 3 was X1 Â 10 8 (P ¼ 0.0001). Acute GvHD (grades II-IV) following DLI from an alternative donor was seen in 3% and 18% of patients post-infusion of 1 Â 10 6 and 1 Â 10 7 CD3+cells, respectively (P ¼ 0.1). GvHD grade IV was seen following two DLI with 1 Â 10 7 CD3+cells. In multivariate analysis, factors predicting GVHD were the number of infusions (o4, P ¼ 0.0004) and pancytopenia post-DLI (P ¼ 0.005) ( Table 4) .
Gamma-glutamyl transferase (gGT)
gGT levels (IU/l) recorded on day +21 after each infusion and on days +45, +60, +90 after the last infusion were found to be significantly increased in patients with GvHD. The median gGT level was 484 IU/l for all patients with GvHD vs 82 IU/l for patients without GvHD (Po0.0001). This significant difference was already present on day +21 (78 vs 275) (P ¼ 0.006), and similarly on day +45 (102 vs 941) (P ¼ 0.006), day +60 (109 vs 584) (P ¼ 0.004), and day +90 (66 vs 400) (P ¼ 0.02) (Figure 3) . Furthermore, the median gGT levels increased if the DLI contained more lymphocytes: the median gGT level was 35 (range 10-1335), 37 (range 8-2823) and 151 (13- non-CML (two LPD, two AML, one ALL). Pancytopenia was a contributing cause of death in five patients, four CML and one ALL. All 13 CML patients who developed pancytopenia responded to DLI and became Ph negative (P ¼ 0.0007). The median time for pancytopenia to develop was 90 days from the last DLI. Median blood counts at the time of pancytopenia were as follows: platelets 26 Â 10 6 / mmc (range 3-189), Hb: 7.8 g/dl (range 7-10), neutrophils: 0.9 Â 10 9 /l (range 0.1-2.1). The median duration of pancytopenia was 90 days (range 60-240). Two patients required reinfusion of donor peripheral blood stem cells.
Treatment-related mortality (TRM)
Nine patients died as a consequence of DLI (five of GvHD, four of infections), five of them received DLI from HLA identical siblings (three had received 10 8 /kg lymphocytes), four from alternative donors (three had received 10 7 /kg lymphocytes). The actuarial probability of treatmentrelated mortality was 9% for HLA identical siblings and 44% for alternative donor transplants (P ¼ 0.006) (Figure 4 ).
Overall survival (OS)
The overall actuarial survival at 10 years is 36%. It is 59% for CML and 17% for non-CML patients (P ¼ 0.0001). Survival at 5 years is 67%, 68%, 72%, 21% and 0%, respectively, when patients are stratified for type of relapse at DLI (molecular, cytogenetic, hematologic, accelerated, resistant or no induction) ( Figure 5 ).
Disease free survival (DFS)
When both mortality and relapse are considered as events (DFS), the actuarial probability at 5 years is 67%, 60%, 48%, 11% and 0%, respectively, in the five relapse groups (Po0.00001) ( Figure 6 ).
Discussion
We have shown that: (a) response to DLI is predicted by tumor burden and is associated with pancytopenia and On day +21 postinfusion, it is 275 for patients with GvHD vs 78 (Po0.006), this significant difference is found on day +45 (Po0.006), on day+60 (Po0.004) and on day +90 (Po0.002). GvHD; (b) GvHD is influenced by DLI regimen and can be predicted on day +21 by serum gGT levels; and (c) patients receiving unrelated donor DLI have a significantly higher mortality as compared to HLA identical DLI. The correlation of tumor burden and response to DLI has been described for CML, 19 but is less clear for patients with other hematologic malignancies. The issue of whether DLI alone can induce a response in relapsed acute leukemia is unproven: in particular, results of DLI infusions for ALL patients are usually disappointing, [9] [10] [11] and similarly most responses in AML seem to have occurred after reinduction chemotherapy pre-DLI. [9] [10] [11] In this study response to DLI was absent in patients with leukemia not responding to chemotherapy (0%) and very high (100%) in patients with molecular relapse. This includes patients with molecular relapse of ALL who achieved a long-lasting molecular remission after DLI and suggests a definite role of DLI in eliminating minimal residual disease (MRD) in patients with lymphoid malignancies too, as previously described. 12 This finding may justify routine molecular monitoring of MRD in patients with acute leukemia after an allogeneic HSCT. The other patients achieving long-lasting remission had received reinduction chemotherapy and were in morphological remission at the time of DLI. Therefore infusing DLI in a patient with acute leukemia with molecular relapse, in remission after chemotherapy or with untreated hematologic relapse, yielded entirely different results. The stratification of patients into five different subgroups according to type of relapse may seem artificial, but paralleled the probability of achieving and maintaining a response with DLI.
We may take these data to indicate that tumor burden influences response to DLI, when the disease is predominantly in the marrow. Disease localization may be an additional relevant factor: patients with extramedullary disease, such as lymphoma, had a lower chance of responding, in our experience. This is in keeping with the description of extramedullary relapses post transplant, in the presence of complete donor chimerism and also extensive chronic GvHD. [20] [21] [22] [23] Finally, myeloma patients did not respond to DLI, but this could be due to the small number of patients, resistant disease or to inadequate lymphocyte dose. 24, 25 It could also be that chemotherapy may also be necessary in myeloma. Indeed, the data we present here show that the majority of patients (61%) receive some form of therapy together with DLI, and it would be appropriate to design prospective trials looking at the impact of additional chemo-immunotherapy in different diseases. Besides tumor burden, pancytopenia and GvHD were the other two predictors of response to DLI. The two events have been described in the experimental model, when allogeneic T cells are infused intravenously in large numbers. 26 The consequence is depletion of the lymphoid organs, pancytopenia, marrow aplasia and GvHD. Similarly, in the clinical setting as well, cytopenia has been shown to be a subclinical disease marker 27 although not part of the original grading system. 28 Since GvHD has long been known to exert an antitumor effect, 29 it comes as no surprise that both GvHD and cytopenia are strong predictors of response to DLI. All CML patients who developed pancytopenia post-DLI, became Ph-chromosome negative.
Once a response to DLI has been achieved, this tends to be long lasting and the actuarial probability of remaining in remission at 5 years is currently 85%. Our longest CML remitter is now 10 years post-DLI and is BCR-ABL negative. 30 GvHD is the major complications of DLI [9] [10] [11] and was seen in 21% of patients in this series. We were able to show that GvHD was more frequent in patients with cytopenia and patients receiving a small number of lymphocyte infusions. This is keeping with the fact that bulk-dose DLI containing large numbers of T cells has a greater chance of inducing GvHD, without improvement in the response rate. 17, 31 In our program we initially used high-dose DLI (1 Â 10 8 T cells), and saw significant GvHD 32 that correlated in severity with the number of T cells infused. Since then we have used an escalating-dose approach, with a starting dose of 1 Â 10 6 cells/kg and a half-log escalation every 21 days, up to a maximum of 5 Â 10 7 T cells/kg. Not all patients completed the program because of GvHD: in particular there was a significant difference between HLA identical and alternative donor DLI. At a dose of 1 Â 10 7 / kg T cells, GvHD II-IV was seen, respectively, in 6 vs 18% of the patients.
The consequence is DLI-related mortality; 9% for the HLA identical sibling DLI and 44% for the alternative donor DLI. Therefore, given the same dose of T cells, GvHD and mortality is significantly different according to donor source, or compatibility. This may call for a different starting dose of T cells in alternative donor transplants, and we have now lowered the initial dose to 1 Â 10 5 /kg, escalating to a maximum 5 Â 10 6 /kg. Another important aspect of post-DLI GvHD is whether one can predict the occurrence of this complication during the course of multiple infusions. We show that serum gGT is a sensitive predictor of GvHD in the absence of other signs or symptoms: on day 21 after DLI gGT serum levels were indeed significantly higher in patients who would subsequently develop GvHD: (275 IU/l vs 78) (P ¼ 0.006).
In conclusion, this study suggests that response of posttransplant relapse to DLI correlates with tumor burden, and that GvHD can be predicted by serum gGT levels. Using reduced numbers of T cells may be explored in alternative donor DLI, since mortality is considerably higher as compared to the situation with identical sibling DLI.
